Pharmacometric analyses of alectinib to facilitate approval of the optimal dose for the first‐line treatment of anaplastic lymphoma kinase–positive non‐small cell lung cancer

Alectinib is an anaplastic lymphoma kinase (ALK) inhibitor approved for treatment of ALK‐positive non‐small cell lung cancer. Population pharmacokinetic (PK) models were developed for alectinib and its major active metabolite M4 using phase I/II PK data in crizotinib‐failed patients (N = 138). The P...

Descripción completa

Detalles Bibliográficos
Autores principales: Hsu, Joy C., Jaminion, Felix, Guerini, Elena, Balas, Bogdana, Bordogna, Walter, Morcos, Peter N., Frey, Nicolas
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2021
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8592510/
https://www.ncbi.nlm.nih.gov/pubmed/34547184
http://dx.doi.org/10.1002/psp4.12702

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8592510/
https://www.ncbi.nlm.nih.gov/pubmed/34547184
http://dx.doi.org/10.1002/psp4.12702

Ejemplares similares